Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 1 |
2020 | 2 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.
Lancet Gastroenterol Hepatol. 2023 May;8(5):446-457. doi: 10.1016/S2468-1253(22)00428-9. Epub 2023 Mar 7.
Lancet Gastroenterol Hepatol. 2023.
PMID: 36898393
Clinical Trial.
Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease.
Daveson AJM, Tye-Din JA, Goel G, Goldstein KE, Hand HL, Neff KM, Williams LJ, Truitt KE, Anderson RP; RESET CeD Study Group.
Daveson AJM, et al.
Aliment Pharmacol Ther. 2020 Jan;51(2):244-252. doi: 10.1111/apt.15551. Epub 2019 Nov 26.
Aliment Pharmacol Ther. 2020.
PMID: 31769533
Clinical Trial.
Item in Clipboard
Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease.
Tye-Din JA, Daveson AJM, Goldstein KE, Hand HL, Neff KM, Goel G, Williams LJ, Truitt KE, Anderson RP; RESET CeD Study Group.
Tye-Din JA, et al.
BMC Med. 2020 Nov 26;18(1):362. doi: 10.1186/s12916-020-01828-y.
BMC Med. 2020.
PMID: 33239013
Free PMC article.
Item in Clipboard
Cite
Cite